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Osteoporosis and the risk of fracture
Abstract
Osteoporosis is a skeletal disease characterised by low bone mass and a deterioration of the microarchitecture of bone
tissue, leading to an increase in bone fragility and a greater risk of fracture. It is a life-threatening disease, with mortality
following hip fracture exceeding mortality after myocardial infarction.1 For women, the risk of dying from the consequences
of a hip fracture is greater than that of dying from breast cancer.2 Moreover, the morbidity associated with hip fracture,
in particular, has an overwhelming impact on patients’ quality of life and places an undue burden on caregivers and the
healthcare system.3 The goal of osteoporosis treatment is to prevent fractures and the subsequent morbidity and mortality
associated with them. More than 90% of all hip and spine fractures in elderly women result from osteoporosis.4 About
20% of patients will die in the following year as an indirect consequence of hip fracture.5 One-third of women who survive
hip fracture will need constant care.6          (SA Fam Pract 2005;47(9): 34-36)
Introduction
Common fracture sites in patients with
osteoporosis are the spine, hip, and
wrist. The gold standard for the diagnosis
of osteoporosis is based on the
measurement of bone mineral density
(BMD) with dual energy X-ray absorp-
tiometry (DXA). Bone mass is determined
per projected area, and the BMD score
obtained correlates with whole-bone
strength.7,8  A diagnosis of osteoporosis
is made if the T-score is below –2.5 at
the spine, femoral neck, or wrist.
The risk of osteoporotic fractures is
not only reflected by low BMD, however.
A range of other factors exist that,
independent of BMD, increase the risk
of fracture (Table I). These factors are
age, female sex, high bone turnover, low
body weight, lifestyle factors, risk of falls,
smoking and excessive alcohol
consumption, medical history of a prior
fracture or family history, and the use of
certain medications such as cortico-
steroids,11 as well as some secondary
causes of osteoporosis. The incidence
of fractures increases with diminishing
BMD. However, fractures frequently
occur in women who have normal BMD,
but other risk factors.12
Understanding bone strength:
The bone quality framework
To answer the question ‘why do bones
break?’, we need to look at a number of
factors that affect bone strength. As with
any structure, the strength of bone
depends on its structural and material
properties. Bone tissue undergoes
continuous renewal through the process
of bone turnover or remodelling. This
process affects both structural and
material properties of bone tissue and
has an impact on bone strength. A
fracture occurs when the applied load
to a bone is greater than its strength.
Bone strength results from a combination
of 3 key factors (Figure 1):
• structural properties
• material properties
• bone turnover rate
To understand the nature of bone
strength, and the Bone Quality
Framework, it is necessary to take all 3
factors into account.
Structural properties
Bone strength is partly determined by
its structural properties: the shape and
size of the bone as well as its
microarchitecture, including trabecular
structures and cortical thickness and
porosity. In osteoporosis, changes in the
trabecular bone architecture weaken the
bone and increase fracture risk. Patients
with hip fracture show a deterioration of
the trabecular architecture of bone tissue,
and the concomitant loss of cross-
connections is associated with an
increased risk of fracture.13
Of particular importance to women
is the observation that dramatic changes
in the trabecular architecture occur over
the period of a year during the first years
after menopause.13 In one study,
vertebral bodies from young healthy
individuals were compared with those
of elderly individuals with osteoporosis.14
In the young individuals, there was a
greater than 2-fold difference in the
amount of trabecular bone in the
vertebral column compared with the
elderly individuals. Cortical shell
thickness in the elderly individuals was
also greatly reduced. The amount of
force required to break the vertebrae of
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an elderly individual with osteoporosis
was nearly 10 times less than that
required to break the vertebrae of a
young, healthy person.
Material properties
In addition to bone structure, the
materials that make up bone tissue are
vital to bone strength. Bone is a
composite of the calcium-containing
mineral hydroxyapatite and the protein
collagen. Cells called osteoblasts
produce the organic matrix component
in its primary form. Collagen obtains its
final conformation outside the osteo-
blasts, where cross-links between
collagen fibres are formed. The collagen
fibres provide a matrix upon which
hydroxyapatite crystals are deposited,
creating a strong composite material.
The degree of mineralization influences
bone strength,15 and the cross-links
between collagen fibres affect the ability
of bone to absorb energy – during a fall,
for example.
Bone turnover
Like any other material exposed to
everyday stresses, bone material will
weaken over time. Fortunately, bone is
a complex living tissue that undergoes
constant renewal to repair the micro-
damage that occurs on a daily basis. In
the bone renewal cycle, bone resorption
is initiated by cells called osteoclasts
that are recruited to the bone surface.
Once on the bone surface, osteoclasts
erode the bone by creating a resorption
cavity. Bone-lining cells differentiate into
o s t e o b l a s t s  t h a t  s e c re t e  a n
unmineralized matrix into the cavity. The
matrix eventually mineralizes, first by a
rapid phase, followed by a more
prolonged phase of mineralization. If the
renewal process proceeds as it should,
the resorption cavity will be completely
refilled with new bone and the bone
surface will be restored. This process of
renewal is called bone remodelling.
Clinical studies have shown that
remodelling increases with age and
reduced oestrogen production. After
menopause, when oestrogen production
ceases, an increase in bone turnover
results in a decrease in mineral density,
because osteoblasts do not completely
fill the resorption cavities created by the
osteoclasts. The increase in bone
remodelling results in a greater number
of resorption cavities, which act as weak
points on the surface of the trabeculae.
When bone turnover does not occur at
all, however, microdamage and
microfractures in trabecular bone cannot
be efficiently repaired. Deterioration of
bone microarchitecture is found in
individuals with high bone turnover, but
not in those with low turnover.16 Strong
bones, therefore, result from an optimal
bone turnover rate.
Future perspectives
The primary targets for the treatment of
osteoporosis are the cells involved in
bone remodelling. Many of the structural
and material properties of bone are
influenced in different ways by
treatments, depending on the nature of
their physiological effects.  Not all the
treatment effects on bone strength are
equally reflected by a measurement of
BMD.
For example, antiresorption treat-
ments that increase BMD by 1–7% lead
to a decrease in vertebral fracture risk
of 40–60%.17 From clinical trials we know
that the increase in BMD accounts for
less than 30% of the reduction in fracture
risk.18,19,20
Understanding the bone quality
factors that contribute to bone strength
will help us better appreciate the concept
that treatment effects on bone strength
have multiple facets. Therefore, the
evaluation of treatments should be done
on the basis of fracture efficacy data,
and not on the basis of one surrogate
end-point such as an increase in BMD.
Currently, some new technologies in
the experimental stage may help
measure the components of bone quality
and how they contribute to bone strength.
These technologies are quantitative
computed tomography (QCT), high-
resolution magnetic resonance imaging
(MRI), and finite element analysis (FEA).
Three-dimensional QCT provides
information on bone geometry, including
trabecular and cortical bone density,
and high-resolution MRI can be used to
carry out an in vivo ‘virtual bone biopsy’
that reveals information about the
trabecular architecture of bone.  FEA is
a computer model designed to predict
bone strength. It integrates material and
structural information and uses imaging
data to create a strength map of the
bone. Some of these techniques hold
promise for future clinical applications.
The goal of osteoporosis treatment is to
prevent fracture and subsequent
mortality and morbidity. Strong bones
fracture less. Treatment approaches,
therefore, should focus on increasing
bone strength. In accordance with the
Bone Quality Framework, strong bones
are a reflection of good bone quality, in
which there is a carefully maintained
balance of structure and material, and
bone turnover occurs at an optimal rate.
Selection of treatments should be based
on available fracture data and not on
BMD measurement alone, as BMD
response does not adequately reflect
the effect of treatment on all the
components of bone strength. A better
understanding of the Bone Quality
Framework and the components that
contribute to bone strength may help
improve the diagnosis and management
of patients at risk for osteoporotic
fracture.
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